NFKB1 and Rett syndrome: Since leriglitazone exerts an anti-inflammatory effect through NF-κB modulation, we studied its effect on the neuroinflammatory landscape in Rett syndrome, noting a correction in leriglitazone-treated animals (Fig. 5A).